In addition, GLI1/2 inhibitors may also be effective in tumours harbouring activating mutations in SMO, or downstream mutations in the HH pathway, as well as in tumours that have acquired resistance to SMO inhibitors. This evidence concerns the gene GLI1 and neoplasm.